FINWIRES · TerminalLIVE
FINWIRES

Update: Moderna, Merck Shares Rise as Melanoma Therapy Shows 'Statistically Significant Improvement' in Late-Stage Trial

By

(Updates to include the stock movement in the headline and the first paragraph.)

Moderna (MRNA) shares climbed 98% and Merck (MRK) shares gained 9% in Wednesday trading after the companies said a late-stage trial of intismeran autogene in combination with Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma.

The combination demonstrated statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival compared with Keytruda alone, the companies said.

The trial will continue to evaluate other secondary endpoints, such as overall survival, the companies said.

Safety profiles of intismeran and Keytruda were consistent with previously reported results, with no new safety signals, the companies said.

Price: $145.76, Change: $+10.59, Percent Change: +7.83%

Related Articles

Wire

Virgin Australia's Velocity Frequent Flyer Receives ACCC Interim Authorization to Continue 7-Eleven Partnership

Virgin Australia's (ASX:VGN) Velocity Frequent Flyer loyalty program has received interim authorization from the Australian Competition and Consumer Commission (ACCC) to continue its retail earn partnership with 7-Eleven Stores and its franchisees, according to a Wednesday statement from the regulator.The authorization allows Velocity members to continue earning points when making purchases at 7-Eleven stores.The airline's shares fell past 1% in recent Wednesday trade.

ASX:VGN
Wire

Update: Mercury Systems Shares Fall After Fiscal Q4 Adjusted Earnings Miss

(Updates with stock price movement in the headline and the first paragraph.)Mercury Systems (MRCY) shares fell 11% during after-hours trading on Tuesday after the company posted lower-than-expected fiscal Q4 adjusted earnings.The company reported fiscal Q4 adjusted earnings late Tuesday of $0.37 per diluted share, down from $0.47 a year earlier.Analysts polled by FactSet expected $0.38.Revenue for the quarter ended July 3 rose to $289.8 million from $273.1 million a year earlier.Analysts expected $266.1 million.

$MRCY
Wire

Mercury Systems Fiscal Q4 Adjusted Earnings Fall, Revenue Rises

Mercury Systems (MRCY) reported fiscal Q4 adjusted earnings late Tuesday of $0.37 per diluted share, down from $0.47 a year earlier.Analysts polled by FactSet expected $0.38.Revenue for the quarter ended July 3 rose to $289.8 million from $273.1 million a year earlier.Analysts expected $266.1 million.

$MRCY